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Distributed Drug Discovery (D
3) proposes solving large drug discovery problems by breaking them into
smaller units for processing at multiple sites. A key component of the synthetic and computational stages
of D
3 is the global rehearsal of prospective reagents and their subsequent use in the creation of virtual
catalogs of molecules accessible by simple, inexpensive combinatorial chemistry. The ﬁrst section of this
article documents the feasibility of the synthetic component of Distributed Drug Discovery. Twenty-four
alkylating agents were rehearsed in the United States, Poland, Russia, and Spain, for their utility in the
synthesis of resin-bound unnatural amino acids 1, key intermediates in many combinatorial chemistry
procedures. This global reagent rehearsal, coupled to virtual library generation, increases the likelihood that
any member of that virtual library can be made. It facilitates the realistic integration of worldwide virtual
D
3 catalog computational analysis with synthesis. The second part of this article describes the creation of
the ﬁrst virtual D
3 catalog. It reports the enumeration of 24 416 acylated unnatural amino acids 5, assembled
from lists of either rehearsed or well-precedented alkylating and acylating reagents, and describes how the
resulting catalog can be freely accessed, searched, and downloaded by the scientiﬁc community.
Introduction
At Indiana University-Purdue University Indianapolis
(IUPUI), we have developed a concept called “Distributed
Drug Discovery” (D
3).
1 Combinatorial chemistry is central
to its enablement. Herein is reported the ﬁrst example of a
key component of D
3: the distributed rehearsal of reagents
and their subsequent use in real and virtual catalog production.
The Distributed Drug Discovery concept is described in
full detail in the preceding Perspective.
1 Immediately fol-
lowing is an Article providing a speciﬁc application to drug
discovery.
2 The premise of D
3 is that the availability of
simple, inexpensive equipment and procedures for each of
the core scientiﬁc drug discovery disciplines (computational
chemistry, synthetic chemistry, and biochemical screening)
will enable large drug discovery problems to be broken down
into manageable smaller units to be solved at multiple sites
throughout the developing and developed world. The re-
combined and coordinated results of these resources can
inexpensively accelerate the identiﬁcation of leads (primarily
for developing world and other neglected disease targets) in
the early stages of the drug discovery process. In addition,
this effort provides educational and job opportunities in both
the developed and developing worlds while building cultural
and economic bridges for the common good.
Combinatorial virtual catalogs, realistically accessible by
globally distributed synthesis, are key to the implementation
of D
3. In classical combinatorial chemistry, reagent rehearsal
increases the likelihood that any individual member of an
enumerated virtual library can be synthesized from each
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3 also incorpo-
rates this rehearsal process. However, it imposes additional
strong constraints on reagent-rehearsed virtual catalogs: any
member of the library must be accessible by rehearsed or
precedented synthesis, anywhere in the world, using simple,
inexpensiVe equipment and procedures. This article docu-
ments progress toward fulﬁlling this challenge. Part I reports
the ﬁrst successful global reagent rehearsal, conducted by
undergraduate and graduate students in the United States,
Poland, Russia, and Spain. In Part II, a virtual D
3 catalog
based on this work is enumerated and made freely accessible.
Results and Discussion
Part I. Rehearsal of Alkylating Reagents for D
3 Com-
binatorial Chemistry. One of the most common types of
intermediates used in combinatorial chemistry is the resin-
bound natural or unnatural R-amino acid 1 (Scheme 1). The
R-amino acid substructure occurs in 28% of the structures
cited in a recent “Comprehensive Survey of Combinatorial
Library Synthesis”.
3,4 Scheme 1 gives examples of a few of
the published libraries based on 1.
5-11 With the exception
of proline, the proteinogenic R-amino acids differ only in
the identity of their R-substituent. When these substituents
do not occur in nature they are referred to as “unnatural”.
The methodology for the introduction of side chains by
carbon-carbon bond construction has expanded considerably
the availability of these unnatural R-amino acids.
12 Of the
existing routes to such molecules, alkylation chemistry
13 has
played a key role. Thus, introduction of an unnatural side
chain onto the R-position of a suitable glycine or higher
amino acid derivative by alkylation can provide, respectively,
R-substituted or R,R-disubstituted amino acid products.
14-18
Because of the central role of 1 in combinatorial chemistry,
and the ability to greatly expand its numbers through
alkylation chemistry, we chose to focus on rehearsing
alkylating agents R1X for our ﬁrst exempliﬁcation of D
3
synthesis. In the process, we wished to show the likelihood
that undergraduate or graduate students would be able to
make any given member of a resulting virtual D
3 catalog,
further demonstrating the potential of Distributed Drug
Discovery. Accordingly, we modiﬁed our published synthesis
of 1
17c and incorporated the rehearsal into a student com-
binatorial chemistry laboratory that transformed 1 to the
acylated derivatives 5 (Scheme 2). This generic structure 5
would then become the basis of our ﬁrst virtual D
3 catalog.
The time ranges shown in Scheme 2 accommodated the
details of laboratory scheduling in academic institutions at
different geographic locations. Simple, inexpensive “Bill-
Board 6-pack” equipment
1 (Figure 1) was used to carry out
this procedure, six reactions at a time. Every Bill-Board
6-pack had six reaction vessels in a grid of two rows (A and
B) by three columns (1, 2, and 3), and reactions were
correspondingly identiﬁed by “row, column” (e.g., A1-B3).
The equipment was designed to enable the essential steps
common to most solid-phase synthetic procedures: cycles
Scheme 1. Role of Alkylating Agents R1X as Diversity
Reagents for Generating Multiple Combinatorial Libraries
from Key Intermediate 1
Scheme 2. Preparation of Acylated Unnatural Amino Acids
Figure 1. Bill-Board Components and 2 × 3 Experimental Grid.
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cleavage, and collection. One to six students were assigned
to each Bill-Board.
In this ﬁrst demonstration of the distributed process,
twenty-four alkylating agents R1X were rehearsed, often in
quadruplicate, sometimes at geographical locations remote
from one another (Indianapolis, IN; Lublin, Poland; Moscow,
Russia; and Barcelona, Spain). In all cases the quality of
the crude products was assessed by LC/MS to obtain a
marker of the suitability of a given reagent in combinatorial
library generation. This analytical measurement of quality
is not deﬁnitive because UV detection can overlook, among
other things, poor absolute recovery, the presence of insoluble
impurities, or soluble impurities not revealed by the detection
system.
19 Nevertheless, the LC/MS data permits elimination,
from a rehearsed virtual library, products based on alkylating
agents that are clearly problematic. Follow up synthesis and
puriﬁcation conducted at IUPUI allowed the isolation and
characterization of all the unnatural amino acids reported in
this distributed reagent rehearsal study.
Since reagent rehearsal was done by students with little
to no prior experience in either organic synthesis or solid-
phase chemistry, two key elements were incorporated into
the laboratory: (1) Students worldwide conducted the same
“control” alkylation reaction, using R1X ) benzyl bromide
(6) in column 1. (2) The evaluation of new alkylating agents
was replicated by at least one other student or student team.
This worldwide distributed process permits the assessment
of both the quality of the work carried out by any given
student/team and the reproducible efﬁcacy of the evaluated
reagents.
The ﬁrst synthetic rehearsals were conducted at IUPUI,
utilizing four concurrent laboratory sections, to pilot the
process of replicated synthesis in multiple students’ hands.
There were up to 20 students in each section. A total of 65
students operated in 32 teams of two per Bill-Board (192
reactions), with one extra Bill-Board used for the solo
student.
20 The control alkylating agent, benzyl bromide (6),
was used by all students in column 1 (Figure 1). The new
alkylating agents were rehearsed in columns 2 and 3. In these
experiments, the acylating agents used in rows A and B of
the Bill-Board were always Fmoc chloride and 2-naphthoyl
chloride, respectively.
(1). Role of Starting Resin 2 in Product Quality. In this
ﬁrst extensive study, two commercial suppliers, I and II,
were commissioned to produce the starting benzophenone
imine resin 2. For comparison purposes, resin from source
I was used in sections one, two, and four (teams 1-8,
10-17, and 26-33), and resin from source II was used
in section three (teams 18-25). Since all 32 teams
prepared the same product (FmocPhe 5{6}a, see Table
1) in position A1 of their Bill-Boards it was informative
to analyze the quality, as a function of resin source, of
all 32 of these replicated products. Figure 2 shows a
comparison of representative products A1 from teams
using resins from these two suppliers.
In the products obtained from reactions using resin from
I (Figure 2a), there was, in addition to desired product
(5.04 min, M + 1 ) 388, 77%), the universal presence of
three impurities (2.5 min, M + 1 ) 256, 4%; 4.8 min, M
+ 1 ) 445, 11%; 5.3 min, M + 1 ) 494, 8%). The MS
data allowed the tentative assignment of the structures 23,
24, and 25 for these respective peaks (Figure 3). In
contrast, there were insigniﬁcant levels of the impurities
at 2.5 and 4.8 min in samples prepared from resin supplier
II (Figure 2b). The Supporting Information contains a
more complete discussion of the origin of these proposed
impurities 23 and 24 in resin from I,
21 and 25 in both
resins from either I or II.
22
Although resins from I and II were used in the initial
laboratories at IUPUI, because of its higher quality, only resin
from commercial source II was used in subsequent labora-
tories at IUPUI, and in laboratories conducted in Poland,
Russia, and Spain.
(2). Results and Analysis of IUPUI Reagent Rehearsal
Data. These initial laboratories at IUPUI evaluated 17
alkylating agents R1X. Replicated alkylations (2-4 rep-
licates), using the same resin and alkylating agent, gave
strikingly similar results (Table 1). Individual results rarely
differed from the average by more than 3%. As expected,
because of the impurities present in the starting resin from
I (see earlier discussion and Supporting Information) the
purity of alkylation products from this resin was lower
(by ∼15-20%) than those from II (compare, for example,
the results for the Fmoc derivatives 5{7}a through 5{12}a
from alkylating agents 7 through 12, where the ﬁrst two
results for each compound were from resin source I, and
the second two results were from resin source II).
Nevertheless, from the same resin source the alkylation
results are very reproducible. In rare cases, replicated
experiments showed considerable variability. This is to
be expected when so many different researchers (students)
are performing this work for the ﬁrst time. For example,
team 28 obtained none of the expected products 5{15}b
or 5{17}b, whereas three other teams using the same
reagent combinations (teams 12, 13, 29 and 11, 12, 27)
were successful and had similar results (63% ( 3% and
80% ( 8%, respectively) for each of these compounds in
the appropriate Bill-Board positions.
23
(3). Distributed Reagent Rehearsal Worldwide (Po-
land, Russia, and Spain). Encouraged by the success of
the IUPUI student alkylating agent rehearsal, we tested the
ability to further distribute this process to students outside
of the United States. Using the same procedures (with minor
modiﬁcations), equipment, and resin from source II, the
laboratory was ﬁrst replicated in Spain. In 36 separate
reactions, teams at the University of Barcelona (two or
three students per Bill-Board) evaluated control benzyl
bromide (6, six replicates) and six additional alkylating agents
in duplicate (Table 2).
With the exclusive use of starting resin purchased from
supplier II, the Barcelona laboratories obtained excellent
results, providing strong documentation for the ability of
distributed discovery to reproducibly synthesize molecules,
both within the same site, and around the world. Except for
one example (Barcelona, team 3), all the control FmocPhe
samples 5{6}a were synthesized in >92% purity as
16 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.determined by LC/MS (Table 2). This was consistent with
the data generated in the United States at IUPUI, where the
subset of compounds 5{6}a synthesized used starting resin
from the same supplier (II) produced 7 of 8 products in
>93% purity (Table 1).
The Barcelona laboratories also rehearsed, in duplicate,
six new alkylating agents, 26-31. Several points are worth
noting. On the basis of their replicated chemistry, alkylating
agents 26, 27, and 30 should be dependable reagents in
libraries. The data from teams 2 and 3 for 5{28}b indicates
Table 1. Purity of Products from Alkylation Rehearsal at IUPUI (Using Resin from Sources I and II)
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product but with moderate purity.
24
The methoxy-substituted reagents 29 and 31 illustrate
the need for a nuanced interpretation of results. The crude
material recoveries for the methoxy derivatives 5{29}a,b
and 5{31}a,b were notably lower compared to the rest of
the products in this laboratory. These molecules, as anisole
derivatives, are susceptible to Friedel-Crafts reactions.
It is well established in the peptide ﬁeld that, in the
absence of a powerful cation quenching agent (such as
anisole itself), products capable of Friedel-Crafts reac-
tions can reattach themselves to the resin cation generated
in the cleavage process.
25 Accordingly, selective, cleav-
age-condition dependent removal of desired product (by
reattachment to the resin) could mask a successful
alkylation prior to cleavage.
To further demonstrate the ability of the distributed
reagent rehearsal project to provide replicated results in
student laboratories across the globe, laboratories were
carried out in Poland and Russia. The same simple
equipment, procedures, and resin from source II were used.
Table 3 compares a set of molecules prepared at IUPUI
(United States), the University of Barcelona (Spain),
Moscow State University (Russia), and the Lublin School
of Pharmacy (Poland). These results indicate that D
3
syntheses can be carried out at multiple global locations
and afford reproducible results.
An additional alkyating agent, 5-(chloromethyl)-2-chlo-
ropyridine (32), was evaluated only at the Moscow site. The
product 5{32}a (Figure 4) was obtained in 76% purity (LC/
MS analysis). Follow up synthesis and puriﬁcation at IUPUI
conﬁrmed the Moscow results.
(4). Conﬁrmation of Rehearsed Reagent Results. To
fully characterize products from the reagent rehearsal and
conﬁrm that student-generated results can reliably predict
synthetic outcomes, all of the listed alkylating agents were
subsequently re-evaluated by a postdoctoral fellow at
IUPUI. Using resin from source II, the Fmoc derivative
of each alkylated product was resynthesized, puriﬁed, and
Figure 2. Representative UV trace from LC/MS analysis of A1
from either resin supplier I or II. (a) LC trace of product (team 1,
Al) using resin from supplier I. (b) LC trace of product (team 18,
Al) using resin from supplier II.
Figure 3. Proposed structures for impurities produced from resin
source I.
Table 2. Alkylating Agent Rehearsal Purity Results from
University of Barcelona
18 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.characterized. The experimental procedure used was
identical to that employed in the rehearsal laboratories at
IUPUI. The results, summarized in Table 4, conﬁrm the
ability of student rehearsed chemistry to be replicated by
a third party. These results also resolved the questions
arising from the large variability of results in the rehearsal
of reagents 28 and 29 reported in Table 2. In addition,
the single result reported by the Moscow site for reagent
32 was conﬁrmed. The Supporting Information provides
LC/MS data for all the crude products from Indianapolis,
Lublin, and Moscow, along with NMR data for all the
puriﬁed, new compounds prepared.
In summary, these ﬁrst reagent rehearsal laboratories
document a key requirement of the Distributed Drug
Discovery concept: the global ability of students to
evaluate reagents and reproducibly make new potential
drug leads, using simple, inexpensive equipment and
procedures. These reagents are now acceptable as input
in the enumeration of the D
3 accessible virtual catalogs
to be described in Part II.
Part II. Virtual D
3 Catalog Enumeration for Open-
Access Availability. An essential component of Distributed
Drug Discovery is the open-access availability of databases
of molecules accessible through distributed chemistry.
Computational chemists can then analyze these large data-
bases to identify and make globally available smaller
databases of potential drug leads targeted for developing
world diseases. Subsequently, the synthesis of the selected
molecules can be carried out, in a distributed fashion, at sites
across the world.
The compounds (including stereoisomers when appropri-
ate) in this virtual D
3 catalog were enumerated with
commercial software.
26 To ensure that virtual library genera-
tion is not limited by cost we also enumerate libraries with
alternative software currently available for free to academia.
27
The complete virtual D
3 catalog is available online through
the Collaborative Drug Discovery interface.
28
On the basis of the distributed chemistry developed and
reported in this article, two types of library enumeration were
envisioned. Each structure made in the reagent rehearsal can
be stored in a library. However, a much larger, “virtual” D
3
catalog (including the compounds actually made) can be
enumerated from all combinations of rehearsed or otherwise
well-precedented reagents used at the variable alkylation and
acylation steps.
To illustrate this process, we assembled lists of accept-
able, commercially available, alkylating and acylating
agents (Tables 5 and 6, respectively) to enumerate a
representative virtual D
3 catalog of acylated unnatural
amino acids (Scheme 2). For the alkylation step extensive
precedence is available, both from our solution-
26 and
solid-phase
17 studies and those of others,
18 to predict the
reactivity of Schiff base esters and related systems with
these electrophiles under a variety of basic conditions.
14
For example, even though Michael addition reactions were
not rehearsed in the present study, we have conﬁdence,
based on our earlier solid-phase research using resin-bound
Schiff bases and Michael acceptors as electrophiles,
17e,j
that reactants 93-108 (Table 5) can be utilized success-
fully. Table 5 also lists references
2,16-18,29 that provide
precedence for these choices.
30 In the future, we plan to
incorporate all rehearsed reagent information into a single
database to further assist reagent selection.
In the acylation step reported in this work, acid chlorides
were utilized as the second variable reagent. However, we
have since modiﬁed our D
3 laboratories to use carboxylic
acids to form the amides by traditional carbodiimide medi-
ated couplings.
31 This makes available a much wider
repertoire of inexpensive reactants for enumeration at the
second variable position. Because the reactivity of carboxylic
acids in forming amide bonds is extensively documented,
simple chemical intuition and reactivity considerations were
used to select the 100 carboxylic acids (Table 6) for
enumeration.
On the basis of these considerations, a virtual D
3 catalog
of 24 416 acylated unnatural amino acids 5 was enumerated.
As discussed in the following article,
2 an additional 24 192
methyl esters of these acylated unnatural amino acids were
enumerated on the basis of the cleavage of resin-bound
products 4 by methanolysis. Thus, a total of 48 608 unique
products are available for D
3 catalog access and searching.
The 100 commercially available alkylating agents and
Michael acceptors
2,14-18,29 and 100 carboxylic acids used
to perform these enumerations are shown in Tables 5 and 6,
respectively.
The catalog of acylated unnatural amino acids contains
more than the 20 000 members that would arise from a
simple 100 × 100 combinatorial process. This is caused
by the formation of stereoisomers in the alkylation step
Table 3. Comparison of Crude Purities of Products Synthesized
at Multiple Sites
a Average of six after dropping highest and lowest values.
b Average
of four after dropping highest and lowest values. (Resin II was used for
the products reported at all four sites).
c The required reagents were not
available.
Figure 4. Moscow single-site result.
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present in the alkylating or acylating reagents. Thus, from
two to eight stereoisomers appear for each structure in
the virtual D
3 catalog. The separate listing of each of these
anticipated stereoisomeric products allows appropriate
computational discrimination and selection when three-
dimensional modeling software is employed and chirality
is important.
Table 7 contains some examples illustrating the range
of this stereochemical complexity. Two stereoisomers arise
when there are no other stereogenic elements in either
the electrophile or the acid [e.g., (R)-5{12,207} plus
enantiomer] or when the electrophile or acid is present as
a single enantiomer (R,R)-5{22,117} plus diastereomer]
or geometric isomer (R,E)-5{82,208} plus enantiomer].
Table 4. Results Obtained by Postdoc (PD) Compared with Previous Compiled Results from Rehearsal Labs (RL) in Indianapolis,
Barcelona, Lublin, and Moscow
a Two different resin sources, I or II. See text for discussion.
b RL ) averaged results from student rehearsal laboratories; PD ) result from postdoc
synthesis at IUPUI.
c Overall puriﬁed yield for four step synthesis.
d Single value, other value was 0%.
20 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.Table 5. One Hundred Commercially Available Electrophiles (84 Alkyl Halides and 16 Michael Acceptors) for Enumeration of
24 416-Member Library
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racemic or prochiral electrophile or a racemic carboxylic
acid is used (S,S)-5{18,121}o r(R)-5{93,159} plus three
other stereoisomers for each]. Eight stereoisomers arise
when both a racemic electrophile and a racemic carboxylic
acid are used (R,R,R)-5{47,186} plus seven other stere-
oisomers].
The synthesis of stereoisomeric mixtures of unnatural
amino acid derivatives has the advantage of providing
stereoisomers for evaluation. It is not uncommon to carry
out initial biochemical screening with mixtures of stere-
oisomers. The follow up work to identify the active
stereoisomer can be accomplished, without stereoselective
synthesis, through bioassay guided fractionation
32 or chiral
chromatography.
33 The active stereoisomer identiﬁed by
these techniques can be subsequently prepared by known
stereoselective synthetic routes,
12,14-16,17g,j,18,34 separation
techniques,
33 or resolution procedures.
35
Table 5. Continued
22 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.Table 6. On Hundred Commercially Available Carboxylic Acids Used for Enumeration of 24 416-Member Library
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24 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.It is important to consider potential side-reactions during
the various steps of the synthesis of acylated unnatural
amino acids 5. For example, the tert-butyl esters present
in resin-bound products 4 that originated in the reactants
used for alkylation, Michael addition, or acylation (36,
75, 96) will be converted to the carboxylic acids during
TFA cleavage.
36 Likewise, the t-butyl carbamate (N-Boc)
group in reactant 83 will be cleaved to the free indole
NH on TFA cleavage to products 5.
37 A lead reference
for each of these subsequent reactions is noted with the
respective reactant,
38 and this is reﬂected in the enumer-
ated product structures. Other more subtle side reactions
will be incorporated into the enumeration products as they
are discovered on the basis of literature precedence or
rehearsal of reagents by our group or by others.
39
To illustrate the variety of virtual molecules available
through this enumeration, 32 examples are shown in Ta-
ble 7.
The open-access availability of this virtual D
3 catalog
makes possible the global computational selection of can-
didates for drug synthesis, while simultaneously enabling the
prioritization of future reagent rehearsals. When computa-
tional analysis suggests a particular library member may be
a drug lead for a developing world disease target, that
molecule will be selected for distributed synthesis. If the
reagent used as input in its enumeration is unrehearsed, the
synthesis will evaluate its suitability as a reagent and enable
it to become a part of this expanding rehearsed reagent
database, stored electronically and available through open-
access.
Summary and Conclusion
This project demonstrates the power and potential of a
globally distributed synthetic process. Students carry out,
using simple procedures and inexpensive equipment, world-
wide replicated solid-phase combinatorial chemistry, rehears-
ing new reagents and generating new compounds for library
production. At the same time they learn and develop
important synthetic skills and methodologies. The data
generated and reported here allows the construction of a
globally accessible D
3 database of well-documented alky-
lating agents and Michael acceptors for the synthesis of resin-
bound unnatural amino acids 1. This intermediate can then
be incorporated into a wide variety of published combina-
torial chemistry procedures. Virtual D
3 catalogs based on
rehearsed or well-precedented reagents and inexpensive
global procedures are essential to the goals of Distributed
Drug Discovery. Accordingly, we have enumerated a 24 416-
member virtual D
3 catalog of acylated unnatural amino acids
5 based on the current work. Freely available virtual D
3
catalogs, such as the one reported in this article, can be
computationally analyzed to select potential drug leads for
developing-world and other neglected diseases. In turn, the
distributed reagent rehearsal provides strong precedent and
documented procedures to successfully make, through dis-
tributed synthesis, any of the molecules selected by this
process.
Experimental Section
General Methods. Organic solvents were of reagent grade
and were used directly without puriﬁcation. Anhydrous NMP,
chloroform-d1, 2-ﬂuorobenzyl bromide, 4-ﬂuorobenzyl bro-
mide, 2-(triﬂuoromethyl)benzyl bromide, 4-(triﬂuorometh-
yl)benzyl bromide, 2-bromobenzyl bromide, allyl bromide,
2-nitrobenzyl bromide, 2,4-dichlorobenzyl chloride, and
benzyl 2-bromoacetate and were purchased from Acros
Organics. Triﬂuoroacetic acid and hydrochloric acid were
obtained from Fisher Scientiﬁc. BTPP (tert-butyl-imino-
tri(pyrrolidino)phosphorane).
16r and Fmoc chloride were
purchased from Fluka. 5-(Chloromethyl)-2-chloropyridine,
N,N-diisopropylethylamine, benzyl bromide, 3-ﬂuorobenzyl
chloride, 3-(triﬂuoromethyl)benzyl chloride, 3-bromobenzyl
bromide, 4-bromobenzyl bromide, 2-(bromomethyl)benzoni-
trile, 3-(bromomethyl)benzonitrile, 4-(bromomethyl)benzoni-
trile, 2-iodobenzyl bromide, 4-iodobenzyl bromide, 1-(chlo-
romethyl)naphthalene, 2-(bromomethyl)naphthalene, 4-meth-
oxybenzyl bromide, 3-methoxybenzyl bromide, and methanol-
d4 were obtained from Aldrich Chemical Co. All resins were
purchased from Midwest Bio-Tech Laboratories (resin I) or
Polymer Laboratories (resin II) unless otherwise noted. All
reactions and washes were conducted at ambient temperature
unless otherwise noted.
Manual solid-phase organic syntheses at ambient temper-
ature were carried out in 3.5 mL fritted glass reaction vessels
Table 6. Continued
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silicon septa on the Bill-Board set, which was designed by
one of us (WLS) as inexpensive equipment
40 to simplify and
expedite multiple, manual solid-phase syntheses. The Bill-
Board reaction vessel components are available from Chem-
Glass: IUP-0305-270H for 3.5 mL reaction vessel; IUP-
Table 7. Representative Examples of 24 416 Member Library (Listed in Ascending Order {n})
26 Journal of Combinatorial Chemistry, 2009 Vol. 11, No. 1 Scott et al.0305-280H (polypropylene screw cap); IUP-0305-281H
(Teﬂon faced silicone septa).
Analytical thin layer chromatography (TLC) was per-
formed with Merck silica gel 60 F254, 0.25 mm precoated
glass plates. TLC plates were visualized using UV254. Flash
column chromatography was performed on silica gel 60
(230-400 mesh) from Silicycle Chemical Division. The
yields of the ﬁnal compounds, after chromatographic
puriﬁcation, were calculated on the basis of the initial
loading of the starting resins and are the overall yields of
all reaction steps starting from these resins.
1H NMR spectra were recorded at 200 MHz (Varian
spectrometer) using TMS (0.00 ppm) and chloroform-d1
mixed with methanol-d4 (3-10%). Electrospray ionization
mass spectrometry was conducted using a PESciex API III
triple stage quadrupole mass spectrometer operated in either
positive-ion or negative-ion detection mode.
The composition of reaction mixtures was determined
based on the integration of NMR spectra as well as LC-
MS results. LC-MS analyses were conducted using an
Agilent system, consisting of a 1100 series HPLC con-
nected to a diode array detector and a 1946D mass
spectrometer conﬁgured for positive-ion/negative-ion elec-
trospray ionization. The LC-MS samples were analyzed
as solutions in CH3CN, prepared at 0.08-0.12 mg/mL
concentration. The LC-MS derived composition of mix-
tures was determined based on UV integration at 210 nm.
General Procedures for Manual Solid-Phase Organic
Synthesis. (a). Distribution of Resin and Alkylation (2
to 3). Depending on the number of reactions to be performed,
resin 2 was distributed either by weight or as aliquots from
an isopycnic suspension. In the case of distribution by
volume from an isopycnic suspension, the Bill-Boards were
placed in their drain trays, and from a neutral buoyancy
suspension in CH2Cl2/NMP, 50 µmols of the benzophenone
imine of glycine Wang resin (2, the resin loading is 0.7 -
0.9 mmol/g) was distributed, via repeated 1 mL aliquots, to
each of the six reaction vessels in a given Bill-Board 6-pack.
During the distribution of the resin, the isopycnic solvent
was allowed to drain through the frit in the reaction vessels.
When distribution was complete, residual solvent was
removed with an “air-push” from a disposable plastic pipet
(Fisher, 13-711-23) ﬁtted with a pierced septum (Aldrich,
Z 12743-4). The resin was washed with NMP (3 × 3 mL)
(this NMP wash was also done when resin was weighed out
into reaction vessels). The bottom of each reaction vessel
was then capped, and a new calibrated pipet (Fisher, 13-
711-24) was used for adding each alkylation reagent in the
following step.
The ﬁrst
1R1-X (benzyl bromide) [0.5 mL of a 0.20 M
solution in NMP, 100 µmols, 2 equiv] was added to the resin
in the two reaction vessels in the ﬁrst column positions (i.e.,
A1 and B1). Then the second
2R1-X [0.5 mL of a 0.20 M
solution in NMP, 100 µmols, 2 equiv] was added to the resin
in the two vessels in the second column positions (i.e., A2
and B2). Finally, the third
3R1-X [0.5 mL of a 0.20 M
solution in NMP, 100 µmols, 2 equiv] was added to the resin
in the two vessels in the third column positions (i.e., A3
and B3). Base was then added [0.5 mL of a 0.20 M solution
of BTPP in NMP, 100 µmols, 2 equiv] to each of the six
reaction vessels. The tops of all reaction vessels were capped,
and the Bill-Board was placed in a rotation apparatus.
Depending on the school location and laboratory schedule,
the reaction was allowed to proceed from 24 h to 2 days
with rotation. This and all subsequent reactions were
performed at room temperature.
(b). Hydrolysis (3 to 1). The Bill-Board was removed
from the rotation apparatus and, after inverting the board,
the bottom caps were removed. The Board was then placed,
top side up, in the drain tray, the top caps were removed,
and the reagents from the alkylation step were allowed to
drain, followed by an air-push. The alkylated resin-bound
resin products 3 were washed with THF (1 × 3 mL). Using
6 clean caps, the bottom of each reaction vessel was capped,
a n da1Naqueous HCl/THF solution (1:2, 2.5 mL) was
added to each of the six reaction vessels. The caps were then
put on the top of each vessel, and the Bill-Board was returned
to the rotator for 20 min. The reagents and byproduct from
the hydrolysis were then removed from hydrolyzed resin-
bound product (1) by ﬁltration and washing with THF (1 ×
3 mL) and then NMP (1 × 3 mL).
(c). Acylation (1 to 4). The bottom of each reaction vessel
was capped, and the acylating agent,
1R2COCl [0.5 mL of a
0.30 M solution of R2COCl in NMP, 150 µmols, 3 equiv]
was added to the resin 1 in each of the three vessels in row
A (A1, A2, and A3). Then the second acylating agent,
2R2COCl [0.5 mL of a 0.30 M solution of R2COCl in NMP,
150 µmols, 3 equiv] was added to the resin 1 in each of the
three vessels in row B (B1, B2, and B3). This was followed
by addition of DIEA [0.5 mL of a 0.30 M solution in NMP,
150 µmols, 3 equiv] to each of the six reaction vessels. The
tops of the reaction vessels were capped, and the reaction
was allowed to rotate overnight or up to 5 days (again,
dependent on school laboratory schedules).
(d). Cleavage of Products from Resin (4 to 5). Acylated
resin product 4 was washed with NMP (2 × 3 mL), THF (2
× 3 mL), and CH2Cl2 (3 × 3 mL). The product was cleaved
from resin with TFA/H2O (95:5, 2 mL) for 30 min. The
ﬁltrate from the cleavage reaction was collected, and the resin
was washed with TFA/H2O (95:5, 2 mL) and CH2Cl2 (1 ×
2 mL). After each collection vial was swirled to thoroughly
mix the cleavage and rinse solutions, a sample of each
solution (100 µL) containing product 5 was transferred to
an autosampler vial for LC/MS analysis. The cleavage
solvent and rinses were evaporated with a simple, inexpen-
sive apparatus.
40 designed to speed up the evaporation with
a stream of nitrogen, in a contained system, while trapping
the evaporating TFA in 2 N NaOH.
General Procedure for Puriﬁcation of Crude Products.
Puriﬁcation of the crude product was performed via ﬂash
column chromatography, using the glass fritted reaction
vessel (3.5 mL) loaded with bulk silica gel (650-700 mg).
The crude product was dissolved in CH2Cl2 and, if necessary,
MeOH (total solution volume e0.5 mL) and applied to the
column. Then a gradient of eluting solvent was applied
starting with CH2Cl2 to CH2Cl2/MeOH/H2O (300:10:0.5).
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described above at ambient temperature under a ﬂow of
nitrogen.
Variations on General Procedure. (a). Indianapolis.
Each of the four separate laboratories operated on a Monday/
Wednesday cycle. The alkylations were begun on the ﬁrst
day. Forty eight hours later (Wednesday), the reactions were
worked-up; the imine was hydrolyzed and worked-up, and
the acylation reactions were begun. Five days later (the
following Monday), the acylation reactions were worked-
up; the product was cleaved from the resin, and samples
taken for TLC and LC/MS analysis. All samples were
analyzed by LC/MS in the analytical department at Eli Lilly
& Company (Indianapolis).
(b). Barcelona, Moscow, and Lublin. At each of these
locations, the complete laboratory was conducted over a
three consecutive day period. The alkylations were begun
on the ﬁrst day. The next day the reactions were worked-
up; the imine was hydrolyzed and worked-up, and the
acylation reactions were begun. The next (and last) day the
acylation reactions were worked-up; the product was cleaved
from the resin, and samples taken for TLC and LC/MS
analysis. The Barcelona samples were analyzed by an LC/
MS available on site. The samples from Moscow and Lublin
were taken back to Indianapolis where they were analyzed
by LC/MS in the analytical department at Eli Lilly.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]phenylala-
nine [5{6}a]: 6.9 mg (35% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 82%, tR ) 5.11 min;
1HN M R
(200 MHz, CDCl3/CD3OD) δ 3.00-3.14 (m, 1H), 3.20 (dd,
J ) 13.9 Hz, J ) 5.5 Hz, 1H), 4.14-4.27 (m, 1H),
4.28-4.49 (m, 2H), 4.59 (t, J ) 5.8 Hz, 1H), 7.16 (m, 2H),
7.23-7.46 (m, 7H), 7.52-7.62 (m, 2H), 7.78 (d, J ) 6.8
Hz, 2H); LC/MS calcd for C24H22NO4 [M + H]
+ 388.1;
found 388.1.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-2-ﬂuoropheny-
lalanine [5{7}a]: 8.3 mg (41% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 83%, tR ) 5.12 min;
1H NMR (200
MHz, CDCl3/CD3OD) δ 3.09 (dd, J ) 14.2 Hz, J ) 7.7 Hz,
1H), 3.32 (dd, J ) 14.2 Hz, J ) 4.9 Hz, 1H), 4.12-4.23
(m, 1H), 4.24-4.44 (m, 2H), 4.61 (t, J ) 5.5 Hz, 1H),
6.96-7.10 (m, 2H), 7.14-7.45 (m, 6H), 7.51-7.60 (m, 2H),
7.76 (d, J ) 7.2 Hz, 2H); LC/MS calcd for C24H21FNO4 [M
+ H]
+ 406.1; found 406.2.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-3-ﬂuoropheny-
lalanine [5{8}a]: 10.0 mg (49% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 82%, tR ) 5.17 min;
1HN M R
(200 MHz, CDCl3/CD3OD) δ 3.08 (dd, J ) 13.8 Hz, J )
6.2 Hz, 1H), 3.19 (dd, J ) 13.9 Hz, J ) 5.5 Hz, 1H), 4.20
(t, J ) 7.0 Hz, 1H), 4.28-4.51 (m, 2H), 4.60 (t, J ) 5.5 Hz,
1H), 6.85-7.00 (m, 2H), 7.17-7.45 (m, 6H), 7.51-7.63 (m,
2H), 7.77 (d, J ) 7.4 Hz, 2H); LC/MS calcd for C24H21FNO4
[M + H]
+ 406.1; found 406.3.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-4-ﬂuoropheny-
lalanine [5{9}a]: 7.0 mg (34% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 97%, tR ) 5.18 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.02 (dd, J ) 13.8 Hz, J )
6.0 Hz, 1H), 3.15 (dd, J ) 14.1 Hz, J ) 5.3 Hz, 1H), 4.19
(t, J ) 6.7 Hz, 1H), 4.28-4.52 (m, 2H), 4.56 (m, 1H), 6.95
(m, 2H), 7.05-7.15 (m, 2H), 7.28-7.46 (m, 4H), 7.52-7.61
(m, 2H), 7.77 (d, J ) 7.2 Hz, 2H); LC/MS calcd for
C24H21FNO4 [M + H]
+ 406.1; found 405.8.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-2-(triﬂuorom-
ethyl)phenylalanine [5{10}a]: 12.2 mg (54% isolated yield)
following chromatographic puriﬁcation (CH2Cl2/MeOH/H2O,
300:10:0.5); initial LC/MS purity 94%, tR ) 5.46 min;
1H
NMR (200 MHz, CDCl3/CD3OD) δ 3.10 (dd, J ) 14.2 Hz,
J ) 9.6 Hz, 1H), 3.46 (dd, J ) 14.7 Hz, J ) 5.1 Hz, 1H),
4.07-4.20 (m, 1H), 4.21-4.36 (m, 2H), 4.64 (dd, J ) 9.5
Hz, J ) 5.1 Hz, 1H), 7.24-7.48 (m, 7H), 7.54 (t, J ) 6.6
Hz, 2H), 7.64 (d, J ) 7.4 Hz, 1H), 7.75 (d, J ) 7.4 Hz,
2H); LC/MS calcd for C25H19F3NO4 [M + H]
+ 456.1; found
456.2.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-3-(triﬂuorom-
ethyl)phenylalanine [5{11}a]: 9.4 mg (41% isolated yield)
following chromatographic puriﬁcation (CH2Cl2/MeOH/H2O,
300:10:0.5); initial LC/MS purity 90%, tR ) 5.53 min;
1H
NMR (200 MHz, CDCl3/CD3OD) δ 3.14 (dd, J ) 13.8 Hz,
J ) 6.0 Hz, 1H), 3.26 (dd, J ) 13.7 Hz, J ) 5.3 Hz, 1H),
4.19 (t, J ) 6.6 Hz, 1H), 4.27-4.51 (m, 2H), 4.61 (t, J )
5.5 Hz), 7.28-7.50 (m, 8H), 7.51-7.62 (m, 2H), 7.77 (dd,
J ) 7.4 Hz, 2H); LC/MS calcd for C25H19F3NO4 [M + H]
+
456.1; found 456.1.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-4-(triﬂuorom-
ethyl)phenylalanine [5{12}a]: 9.4 mg (41% isolated yield)
following chromatographic puriﬁcation (CH2Cl2/MeOH/H2O,
300:10:0.5); initial LC/MS purity 88%, tR ) 5.55 min;
1H
NMR (200 MHz, CDCl3/CD3OD) δ 3.12 (dd, J ) 13.7 Hz,
J ) 5.9 Hz, 1H), 3.26 (dd, J ) 14 Hz, J ) 5.6 Hz, 1H),
4.19 (t, J ) 6.6 Hz, 1H), 4.30-4.54 (m, 2H), 4.63 (t, J )
5.3 Hz, 1H), 7.21-7.46 (m, 6H), 7.47-7.61 (m, 4H), 7.77
(d, J ) 7.2 Hz, 2H); LC/MS calcd for C25H19F3NO4 [M -
H]
- 454.1; found 454.2.
2-Bromo-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{13}a]: 11.2 mg (48% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5): initial LC/MS purity 90%, tR ) 5.39 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.12 (dd, J ) 13.8 Hz, 9.2
Hz, 1H), 3.44 (dd, J ) 14.1 Hz, 5.3 Hz, 1H), 4.05-4.40
(m, 3H), 4.68 (dd, J ) 8.8 Hz, 5.1 Hz, 1H), 7.03-7.16 (m,
1H), 7.18-7.45 (m, 6H), 7.55 (d, J ) 7.6 Hz, 3H), 7.76 (d,
J ) 7.4 Hz, 2H); LC/MS calcd for C24H21BrNO4 [M + H]
+
466.1; found 468.0.
3-Bromo-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{14}a]: 10.7 mg (46% isolated yield) following
chromatographic puriﬁcation (CH2Cl/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 97%, tR ) 5.49 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.05 (dd, J ) 13.8 Hz, 6.6
Hz, 1H), 3.17 (dd, J ) 13.9 Hz, 5.5 Hz, 1H), 4.15-4.51
(m, 3H), 4.59 (t, J ) 5.5 Hz, 1H), 7.06-7.21 (m, 2H),
7.30-7.46 (m, 6H), 7.52-7.63 (m, 2H), 7.77 (d, J ) 7.4
Hz, 2H); LC/MS calcd for C24H21BrNO4 [M + H]
+ 466.1;
found 466.1.
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9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{15}a]:9.8 mg (42% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 98%, tR ) 5.52 min;
1HN M R
(200 MHz, CDCl3/CD3OD): δ 3.03 (dd, J ) 13.6 Hz, J )
6.1 Hz, 1H), 3.15 (dd, J ) 14.4 Hz, J ) 5.8 Hz, 1H), 4.19
(t, J ) 6.2 Hz, 1H), 4.28-4.51 (m, 2H), 4.52-4.62 (m, 1H),
7.01 (d, J ) 8.4 Hz, 2H), 7.31-7.46 (m, 6H), 7.53-7.62
(m, 2H), 7.78 (d, J ) 7.0 Hz, 2H); LC/MS calcd for
C24H21BrNO4 [M + H]
+ 466.1; found 467.8.
2-Cyano-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{16}a]: 7.8 mg (38% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 94%, tR ) 4.87 min;
1HN M R
(200 MHz, CDCl3/CD3OD): δ 3.25 (dd, J ) 14.3 Hz, J )
7.7 Hz, 1H), 3.48 (dd, J ) 14.3 Hz, J ) 5.5 Hz, 1H), 4.16
(t, J ) 6.7 Hz, 1H), 4.22-4.44 (m, 2H), 4.60-4.76 (m, 1H),
7.26-7.64 (m, 10H), 7.76 (d, J ) 7.0 Hz, 2H); LC/MS calcd
for C25H19N2O4 [M + H]
+ 413.1; found 413.2.
3-Cyano-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{17}a]: 7.8 mg (38% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 82%, tR ) 4.81 min;
1H NMR (200
MHz, CDCl3/CD3OD) δ 3.09 (dd, J ) 13.8 Hz, J ) 6.2 Hz,
1H), 3.22 (dd, J ) 13.5 Hz, J ) 5.1 Hz, 1H), 4.19 (t, J )
6.4 Hz, 1H), 4.29-4.54 (m, 2H), 4.58 (m, 1H), 7.27-7.62
(m, 10H), 7.77 (d, J ) 7.4 Hz, 2H); LC/MS calcd for
C25H19N2O4 [M - H]
- 412.1; found 411.3.
4-Cyano-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]pheny-
lalanine [5{18}a]: 7.5 mg (36% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 91%, tR ) 4.79 min;
1HN M R
(200 MHz, CDCl3/CD3OD) δ 3.10 (dd, J ) 13.7 Hz, J )
7.2 Hz, 1H), 3.19-3.33 (m, 1H), 4.19 (t, J ) 6.4 Hz, 1H),
4.31-4.55 (m, 2H), 4.56-4.64 (m, 1H), 7.22-7.46 (m, 6H),
7.52-7.62 (m, 4H), 7.78 (d, J ) 7.4 Hz, 2H); LC/MS calcd
for C25H19N2O4 [M - H]
- 412.1; found 412.5.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-2-iodophenyla-
lanine [5{19}a]: 11.4 mg (44% isolated yield) following
chromatographic puriﬁcation (CH2Cl2-MeOH-H2O, 300:10:
0.5); initial LC/MS purity 97%, tR ) 5.51 min;
1HN M R
(200 MHz, CDCl3/CD3OD) δ 3.11 (dd, J ) 14.4 Hz, J )
9.2 Hz, 1H), 3.40 (dd, J ) 13.9 Hz, J ) 5.1 Hz, 1H),
4.09-4.21 (m, 1H), 4.22-4.39 (m, 2H), 4.67 (dd, J ) 9.2
Hz, J ) 5.1 Hz, 1H), 6.86-6.97 (m, 1H), 7.22-7.44 (m,
6H), 7.52-7.61 (m, 2H), 7.75 (d, J ) 7.4 Hz, 2H), 7.83 (d,
J ) 7.8 Hz, 1H); LC/MS: calcd for C24H21INO4 [M + H]
+
514.0; found 514.0.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-4-iodophenyla-
lanine [5{20}a]: 7.1 mg (28% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 97%, tR ) 5.61 min;
1HN M R
(200 MHz, CDCl3/CD3OD): δ 3.01 (dd, J ) 14.2 Hz, J )
6.4 Hz, 1H), 3.14 (dd, J ) 13.7 Hz, J ) 5.3 Hz, 1H), 4.19
(t, J ) 6.6 Hz, 1H), 4.27-4.49 (m, 2H), 4.50-4.62 (m, 1H),
5.82 (d, J ) 8.4 Hz, 1H), 6.89 (d, J ) 8.2 Hz, 2H),
7.27-7.47 (m, 4H), 7.51-7.64 (m, 4H), 7.78 (d, J ) 7.4
Hz, 2H); LC/MS calcd for C24H21INO4 [M + H]
+ 514.0;
found 514.0.
r-[[(
9H-Fluoren-9-ylmethoxy)carbonyl]amino]-1-naph-
thalenepropanoic acid [5{21}a]: 5.9 mg (27% isolated
yield) following chromatographic puriﬁcation (CH2Cl2/
MeOH/H2O, 300:10:0.5); initial LC/MS purity 86%, tR )
5.57 min;
1H NMR (200 MHz, CDCl3/CD3OD) δ 3.38-3.50
(m, 1H), 3.75 (dd, J ) 14.2 Hz, 5.4 Hz, 1H), 4.08-4.22 (m,
1H), 4.23-4.39 (m, 2H), 4.73 (dd, J ) 7.4 Hz, 5.6 Hz, 1H),
7.23-7.55 (m, 10H), 7.70-7.89 (m, 4H), 8.16 (d, J ) 7.8
Hz, 1H); LC/MS calcd for C28H24NO4 [M + H]
+ 438.2;
found 438.2.
r-[[(
9H-Fluoren-9-ylmethoxy)carbonyl]amino]-2-naph-
thalenepropanoic acid [5{22}a]: 8.8 mg (40% isolated
yield) following chromatographic puriﬁcation (CH2Cl2/
MeOH/H2O, 300:10:0.5); initial LC/MS purity 85%, tR )
5.58 min;
1H NMR (200 MHz, CDCl3/CD3OD) δ 3.24 (dd,
J ) 14 Hz, J ) 6.8 Hz, 1H), 3.31-3.45 (m, 1H), 4.12-4.45
(m, 1H), 4.27-4.46 (m, 2H), 4.69 (t, J ) 5.6 Hz, 1H),
7.19-7.56 (m, 10H), 7.64 (m, 1H), 7.71-7.83 (m, 4H); LC/
MS calcd for C28H24NO4 [M + H]
+ 438.2; found 438.2.
2-[[(
9H-Fluoren-9-ylmethoxy)carbonyl]amino]-4-pen-
tenoic acid [5{26}a]: 10.2 mg (60% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 93%, tR ) 4.74 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 2.45-2.71 (m, 2H), 4.23 (t, J
) 6.7 Hz, 1H), 4.30-4.49 (m, 3H), 5.05-5.25 (m, 2H), 5.73
(m, 1H), 7.29-7.46 (m, 4H), 7.61 (d, J ) 7.2 Hz, 2H), 7.77
(d, J ) 6.6 Hz, 2H); LC/MS calcd for C20H20NO4 [M +
Na]
+ 360.1; found 360.1.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-2-nitrophenyla-
lanine [5{27}a]: 9.6 mg (44% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 91%, tR ) 5.00 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.25 (dd, J ) 13.2 Hz, 9.4
Hz, 1H), 3.63 (dd, J ) 13.9 Hz, 5.5 Hz, 1H), 4.06-4.20
(m, 1H), 4.20-4.37 (m, 2H), 4.70 (dd, J ) 8.6 Hz, 5.4 Hz,
1H), 7.27-7.59 (m, 9H), 7.75 (d, J ) 7.2 Hz, 2H), 7.94 (d,
J ) 8.0 Hz, 1H); LC/MS calcd for C24H21N2O6 [M + H]
+
433.1; found 433.2.
2,4-Dichloro-N-[(
9H-ﬂuoren-9-ylmethoxy)carbonyl]phe-
nylalanine [5{28}a]: 8.9 mg (39% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 89%, tR ) 5.71 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.07 (dd, J ) 13.6 Hz, 8.8
Hz, 1H), 3.32-3.46 (m, 1H), 4.16 (m, 1H), 4.22-4.42 (m,
2H), 4.62 (dd, J ) 8.4 Hz, 5.4 Hz, 1H), 7.16 (s, 2H),
7.28-7.45 (m, 5H), 7.49-7.61 (m, 2H), 7.76 (d, J ) 6.8
Hz, 2H); LC/MS calcd for C24H20Cl2NO4 [M + H]
+ 456.1;
found 456.2.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-O-methylty-
rosine [5{29}a]: 10.3 mg (49% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5); initial LC/MS purity 94%, tR ) 5.08 min;
1H NMR
(200 MHz, CDCl3/CD3OD) δ 3.03 (dd, J ) 13.9 Hz, 6.7
Hz, 1H), 3.34 (dd, J ) 13.9 Hz, 5.5 Hz, 1H), 3.77 (s, 3H),
4.19 (t, J ) 6.9 Hz, 1H), 4.25-4.49 (m, 2H), 4.56 (t, J )
5.5 Hz, 1H), 6.82 (d, J ) 7.6 Hz, 2H), 7.07 (d, J ) 8.0 Hz,
2H), 7.29-7.48 (m, 4H), 7.52-7.64 (m, 2H), 7.77 (d, J )
7.2 Hz, 2H); LC/MS calcd for C25H24NO5 [M + H]
+ 418.2;
found 418.2.
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9H-ﬂuoren-9-ylmethoxy)carbony-
l]aspartic Acid [5{30}a]: 7.9 mg (35% isolated yield)
following chromatographic puriﬁcation (CH2Cl2/MeOH/H2O,
300:10:0.5); initial LC/MS purity 84%, tR ) 5.25 min;
1H
NMR (200 MHz, CDCl3/CD3OD) δ 2.94 (dd, J ) 16.7 Hz,
4.5 Hz, 1H), 3.05 (dd, J ) 17.2 Hz, 5.2 Hz, 1H), 4.22 (t, J
) 7.1 Hz, 1H), 4.29-4.45 (m, 2H), 4.62 (m, 1H), 5.15 (s,
2H), 6.18 (d, J ) 8.0 Hz, 1H), 7.26-7.46 (m, 9H), 7.60 (d,
J ) 7.4 Hz, 2H), 7.76 (d, J ) 7.4 Hz, 2H); LC/MS calcd
for C26H24NO6 [M + H]
+ 446.2; found 446.2.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-3-methoxyphe-
nylalanine [5{31}a]: 5.6 mg (27% isolated yield) following
chromatographic puriﬁcation (CH2Cl2/MeOH/H2O, 300:10:
0.5) initial LC/MS purity 89%, tR ) 5.14 min;
1H NMR (200
MHz, CDCl3/CD3OD) δ 3.00-3.26 (m, 2H), 3.76 (s, 3H),
4.14-4.46 (m, 3H), 4.57 (m, 1H), 6.73-6.83 (m, 2H),
7.14-7.46 (m, 6H), 7.52-7.62 (m, 2H), 7.76 (d, J ) 7.0
Hz, 2H); LC/MS calcd for C25H24NO5 [M + H]
+ 418.2;
found 418.2.
N-[(
9H-Fluoren-9-ylmethoxy)carbonyl]-2-(chloropyri-
din-5-yl)alanine [5{32}a]: 5.5 mg (26% isolated yield)
following chromatographic puriﬁcation (CH2Cl2/MeOH/H2O,
300:10:0.5); initial LC/MS purity 80%, tR ) 2.53 min;
1H
NMR (200 MHz, CDCl3/CD3OD) δ 2.75-3.00 (m, 2 H),
3.95 (t, J ) 6.4 Hz, 1 H), 4.06-4.38 (m, 3 H), 6.94-7.22
(m, 6 H), 7.32 (d, J ) 7.2 Hz, 2 H), 7.52 (d, J ) 7.0 Hz, 2
H), 7.90 (s, 1 H); LC/MS calcd for C23H19ClN2O4 [M -
H]
- 421.1; found 421.0.
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